Storia in 2 fonti

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Raccontata da

morningstar.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo3 g fa

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on…

Definium announced Phase 3 results for DT120, a psychedelic-based therapy, in 149 major depressive disorder patients. Psychedelic-inspired therapeutics represent an emerging biotech category; regulatory approval would validate innovative treatment approaches to psychiatric disorders.

originale

benzinga.com3 g fa

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with major depressive disorder — with the…

Leggi questa versione → originale

Timeline cronologica

domenica 21 giugno 2026·morningstar.com
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
lunedì 22 giugno 2026·benzinga.com
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi
Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with…
lunedì 22 giugno 2026·morningstar.com
Definium Therapeutics, Inc. Announces Proposed Public Offering
Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on…

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Timeline cronologica

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on…

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Timeline cronologica

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Definium Therapeutics, Inc. Announces Proposed Public Offering